NCI

Fluorescent nanoparticles clearly identified colonic adenomas — precursors to colorectal cancer — in mice, and the formulation should translate to clinical use in humans. Read More

Vanderbilt researchers detail the landscape of RNA editing — a form of RNA modification — in primary effusion lymphoma cells during Kaposi’s sarcoma-associated herpesvirus infection and identify an edited viral microRNA that is critical for infection. Read More

Researchers at Vanderbilt University Medical Center have discovered why the uropathogenic bacterium E. coli, the leading cause of urinary tract infections, is so tenacious; their findings could lead to new ways to prevent recurrent UTIs. Read More

A team led by Vanderbilt researchers has described and characterized the first zinc metallochaperone: a protein that puts zinc into other “client” proteins. Read More

Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity. Read More

Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity. Read More

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment. Read More

Vanderbilt researchers have received a National Cancer Institute grant to develop a novel, integrative approach to detect early signs of lung cancer. The four-year project builds on a related, recent study that established the value of using three separate measures—structural imaging, a protein marker and information available from electronic health records—to predict lung cancer in... Read More

William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth. Read More

Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer. Read More